Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a randomized controlled trial.

Generalized estimating equation models were fitted to assess impact of teduglutide on SBS-related QoL using data from all visits, adjusted for baseline characteristics.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiology, and bowel anatomy.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Teduglutide (GLP-2 analog) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Teduglutide (GLP-2 analog), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Gastrointestinal Agents, Intestines, Peptides, Quality of Life and Short Bowel Syndrome.

The authors tagged it with the keywords intestinal failure, parenteral nutrition and teduglutide.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teduglutide (GLP-2 analog).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (JPEN. Journal of parenteral and enteral nutrition), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.